Bank Of America Corp Cor Medix Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Cor Medix Inc. stock. As of the latest transaction made, Bank Of America Corp holds 37,977 shares of CRMD stock, worth $275,333. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,977

Previous 28,157 34.88%

Holding current value

$275,333

Previous $119,000 37.82%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.08 - $6.39 $40,065 - $62,749	9,820 Added 34.88%	37,977 $164,000
Q1 2024 May 15, 2024	SELL	$2.94 - $4.24 $101,497 - $146,377	-34,523 Reduced 55.08%	28,157 $119,000
Q4 2023 Feb 14, 2024	BUY	$3.0 - $4.01 $114,339 - $152,833	38,113 Added 155.14%	62,680 $235,000
Q2 2023 Aug 14, 2023	BUY	$3.94 - $5.8 $16,264 - $23,942	4,128 Added 20.2%	24,567 $97,000
Q1 2023 May 12, 2023	BUY	$3.22 - $4.61 $15,552 - $22,266	4,830 Added 30.94%	20,439 $84,000
Q4 2022 Feb 10, 2023	BUY	$2.81 - $4.45 $23,131 - $36,632	8,232 Added 111.59%	15,609 $65,000
Q3 2022 Nov 14, 2022	BUY	$2.82 - $7.52 $284 - $759	101 Added 1.39%	7,377 $21,000
Q2 2022 Aug 12, 2022	SELL	$2.73 - $5.61 $54,138 - $111,251	-19,831 Reduced 73.16%	7,276 $29,000
Q1 2022 May 16, 2022	SELL	$3.83 - $6.24 $110,016 - $179,244	-28,725 Reduced 51.45%	27,107 $148,000
Q4 2021 Feb 08, 2022	BUY	$4.47 - $5.56 $77,532 - $96,438	17,345 Added 45.07%	55,832 $255,000
Q3 2021 Nov 15, 2021	BUY	$4.46 - $7.11 $17,683 - $28,191	3,965 Added 11.49%	38,487 $180,000
Q2 2021 Sep 13, 2021	BUY	$6.05 - $10.09 $208,858 - $348,326	34,522 New	34,522 $237,000

Others Institutions Holding CRMD

# of Institutions

101

Shares Held

16.9M

Call Options Held

70.5K

Put Options Held

358K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $299M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Cor Medix Inc. Transaction History